Animal Models of Tardive Dyskinesia

  • Harold L. Klawans
  • Paul M. Carvey
  • Caroline M. Tanner
  • Christopher G. Goetz


For the last 12 years we have been studying the rodent model of tardive dyskinesia (TD) in both rats and guinea pigs. All of these studies have involved the observation of dopamine agonist-induced behavior following chronic neuroleptic administration. The theoretical basis behind these studies is the assumption that neuroleptic induced alterations of dopaminergic function occur in both TD and these models.1 These models have employed dopamine agonist-induced stereotyped behaviors as the measure of presumed postsynaptic dopamine receptor site functional sensitivity in the striatum.


Dopamine Agonist Tardive Dyskinesia Stereotyped Behavior Dopaminergic Receptor Antipsychotic Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Goetz, C.G., Weiner, W.J., Nausieda, P.A., Klawans, H.L.: Tardive dyskinesia: pharmacology and clinical implications. Clin. Neuropharmacol. 1982; 5: 3–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Rubovits, R, Patel, B.C., Klawans, H.L.: Effect of prolonged chlorpromazine pretreatment on the threshold for amphetamine- induced stereotypy: a model for tradive dyskinesias. Adv. Neurol. 1973; 1: 671–5.Google Scholar
  3. 3.
    Guldberg, H.C., Yates, C.M.: Effects of chlorpromazine on the metabolism of catecholamines in dog brain. Br. J. Pharmacol. 1969; 36:53 5–7.Google Scholar
  4. 4.
    Nyback, H., Sedvall, G.: Effect of chlorpromazine on accumlation and disappearance of catecholamines formed from tyrosine C-14 in brain. J. Pharmacol. Exp. Ther. 1968; 162: 294–8.PubMedGoogle Scholar
  5. 5.
    Klawans, H.L., Rubovits, R.: An experimental model of tardive dyskinesia. J. Neural Transm. 1972; 33: 235–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Tarsy, D., Baldessarini, R.J.: Pharmacologically-induced behavioral supersensitivity to apomorphine. Nature (New Biol.) 1973; 245: 262.Google Scholar
  7. 7.
    Gianutsos, G., Drawbaugh, R.B., Hynes, M.D., Lai, H.: Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci. 1974; 14: 887–98.PubMedCrossRefGoogle Scholar
  8. 8.
    Klawans, H.L., Carvey, P., Nausieda, P.A., Goetz, C.G., Weiner, W.J.: Effect of dose and type of neuroleptic in an animal model of tardive dyskinesia. Neurology (NY) 1980; 30: 95.Google Scholar
  9. 9.
    Goetz, C.G., Carvey, P.M., Tanner, C.M., Klawans, H.L.: Neuroleptic-induced dopamine hypersensitivity. Life Sci. 1984; 34: 1475–1479.PubMedCrossRefGoogle Scholar
  10. 10.
    Goetz, C.G., Klawans, H.L.: Controversies in animal models of tardive dyskinesias. In, Movement Disorders, ed., S. Fahn, C.D. Marsden, pp. 250–263, Butterworth, London, 1982.Google Scholar
  11. 11.
    Snyder, S.H., Banerjee, S.P., Yamamura, H.I., Greenberg, D.: Drugs, Neurotransmitters, and Schizophrenia: Phenothiazines, amphetamines, and enzymes synthesizing psychotomimetic drugs aid schizophrenia research. Science 184: 1243–1253, 1974.PubMedCrossRefGoogle Scholar
  12. 12.
    Hitri, A., Carvey, P., Weiner, W.J., Klawans, H.L.: Biochemical and behavioral studies of neuroleptic induced behavioral supersensitivity. In: Fann, W.E., Smith, R.C., Davis, J.M., Domino, E.F., eds. Tardive Dyskinesia: Research and Treatment. New York: Spectrum Publications, 1980: 145–63CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Harold L. Klawans
    • 1
  • Paul M. Carvey
    • 1
  • Caroline M. Tanner
    • 1
  • Christopher G. Goetz
    • 1
  1. 1.Department of Neurological SciencesRush-Presbyterian St. Luke’s Medical CenterChicagoUSA

Personalised recommendations